ANXA2 and hepatocellular carcinoma: Blocking this interaction reduces the phosphorylation of EGFR and Annexin A2, suppressing mycoplasma-induced invasion and migration of gastric cancer cells [106], and improving the sensitivity of hepatocellular carcinoma cells to chemotherapy drugs [105].